Medical Technology for healthcare professionals
Global website (English)
back
Medical Technology
recommended searches
popular searches
This product is available for US customers only
PRODUCT

ZEISS CT LUCIA 621P

Treating a wide range of cataract patients with a unique ZEISS Optic.

CT LUCIA® 621P IOLs, with ZEISS Optic features, are designed to reduce spherical aberration and at the same time optimize visual outcomes in the event of potential decentration and lens misalignments.

The IOL features a reinforced optic-haptic junction, coupled with step-vaulted C-loop haptics, designed to enable easy centering while maximizing direct capsular contact, thus optimizing stability and supporting a consistent position in the bag. The ZEISS CT LUCIA 621P is supplied in a fully preloaded delivery system.

Get in contact with us
  • Optimized visual outcomes¹
  • Excellent stability
  • Intuitive injector handling

ZEISS CT LUCIA 621P

New generation of aspheric monofocal C-loop IOL
  • Patented ZEISS Optic (ZO) Asphericity Concept
  • Hydrophobic acrylic with heparin-coated2 surface
  • Long-term optical clarity due to the glistening-free3  material
  • Wide Diopter range available in powers ranging from 0.0 to +34.0 in 0.5 diopter steps
  • Fully preloaded delivery system
See all specifications
Fig. 1. Influence of decentration on predicted mesopic visual acuity.

Optimized visual outcomes1

The patented ZEISS Optic (ZO) Asphericity Concept of the ZEISS CT LUCIA 621P was developed to compensate for a wide range of spherical aberrations. It is uniquely designed to be less susceptible to decentration enabling optimized visual outcomes.1.

Find out why

Optimized visual outcomes1

Third-party Content Blocked

The video player is blocked due to your tracking preferences. To change the settings and play the video, please click the button below and consent to use of "Functional" tracking technologies.

Designed to be less susceptible to decentration1

Every eye is as individual as the patient and typically, the human eye is not optically symmetrical, which can lead to IOL decentration. Generally, IOL decentration occurs due to poor capsular or zonular support, decentered capsulorhexis, asymmetric shrinkage of the capsular bag, misplacement of the haptics of the IOL, or luxation in eyes with pseudoexfoliation.

CT LUCIA® 621P IOLs, with ZEISS Optic features, are designed to reduce spherical aberration and at the same time optimize visual outcomes in the event of potential decentration and lens misalignments. With its unique design, CT LUCIA 621P is designed to deliver optimized visual outcomes for a wide range of cataract patients.1

  • 1

    The data is taken from a simulation. The transferability of the results of such a simulation to patients with an actual implanted intraocular lens has not yet been scientifically proven. Whether the simulated impressions correspond to the actual visual impressions must be clarified in future invasive studies.   

Excellent stability

ZEISS CT LUCIA 621P IOLs feature a reinforced optic-haptic junction, coupled with step-vaulted C-loop haptics, designed to enable easy centering while maximizing direct capsular contact, thus optimizing stability and supporting a consistent position in the bag.   

Click here for surgeon assessment

Excellent stability

Fig. 1: The behavior of the axial IOL position stability of the ZEISS CT LUCIA 621P over a duration of 1 week and 1 month.   

The anterior chamber stability of the ZEISS CT LUCIA 621P assessed over a period of 1 week and 1 month

The assessment was done by biometry measurement using the ZEISS IOLMaster 700. Anterior chamber depth (ACD) was measured to reflect the position stability of the implanted IOL at the two post-operative visits (1 week (W1) and 1 month (M1)).1

Conclusion:  The IOL demonstrated positional stability over the duration of time with no significant shift in its position in the capsular bag.

  • 1

    Internal report on ZEISS CT LUCIA 621P data collection (Dr Cuttita) - Version 1.1 dated 19.11.2019.   

Intuitive injector handling

The ZEISS CT LUCIA 621P is supplied in a fully preloaded delivery system. Based on survey results, the CT LUCIA 621P scored very highly in the preparatory phase and helped to reduce surgery time as it was intuitive and easy to use.4 In addition, the IOL has a heparin-coated2 surface to allow for a smoother injection and unfolding process.

Click here for more features and usability feedback

Intuitive injector handling

Easy to prepare

Apply ophthalmic viscoelastic. Close the IOL chamber wings.

Step 1

Step 2

Intuitive and easy to use

Intermediate position

Gently push the plunger forward. An audible click indicates that the intermediate position has been reached. The IOL is ready for implantation.

Smooth and controlled injection

The preloaded ZEISS CT LUCIA 621P has a heparin-coated1 surface to allow for a smoother injection and unfolding process. Based on survey results, surgeons reported that in 98% of cases, the IOL always left the injector tip in a reproducible fashion.2

Excellent performance

Based on survey results, 99% of respondents reported that they "agree" or "fully agree" with ease of use with CT LUCIA 621P and preferred it over their current device of choice.2

  • 1

    The heparin coating on the lens surface has no pharmacological, immunological or metabolic action.
  • 2

    Data on file.

ZEISS CT LUCIA 602

Reliable monofocal hydrophobic, 3-piece-IOL performance

The ZEISS CT LUCIA 602 is the 3-piece member of the CT LUCIA family, featuring the patented ZO Asphericity Concept (ZO: ZEISS Optic) designed to compensate for a range of aberrations, providing better image quality in real-life conditions. CT LUCIA® 602 uses highly stable PVDF haptics, designed to ensure IOL stability in the capsular bag.

Learn more

Downloads

Handling instructions video

Third-party Content Blocked

The video player is blocked due to your tracking preferences. To change the settings and play the video, please click the button below and consent to use of "Functional" tracking technologies.

ZEISS CT LUCIA 621P

Smooth and controlled injection



Third-party Content Blocked

The video player is blocked due to your tracking preferences. To change the settings and play the video, please click the button below and consent to use of "Functional" tracking technologies.

ZEISS CT LUCIA 602

Designed for better capsular bag stability

Specification comparison

ZEISS CT LUCIA family
CT LUCIA® 621P
CT LUCIA® 602

Optic Design   

Monofocal, aspheric (aberration correcting)   

Monofocal, aspheric (aberration correcting)

Material   

Hydrophobic acrylic with heparin-coated2 surface

Hydrophobic acrylic with Polyvinylidene fluoride (PVDF) monofilament haptics

Optic Diameter   

6.0 mm   

6.0 mm

Total Diameter   

13.0 mm   

13.0 mm

Haptic   

Step vaulted   

Angulation 5°

Lens Design   

Single-piece   

Three-piece

Incision Size

2.2 – 2.6 mm (depending on diopter)

2.8 mm

Diopter Range   

From 0.0 to +34.0 D, 0.5 D increments

From +4.0 to +34.0 D, 0.5 D increments

Company Labeled A-Constant*

120.2

117.7

ACD*

6.29
4.8

Abbe Number

51

51

Refractive Index   

1.49

1.49

Implantation in   

Capsular bag   

Capsular bag

Injector / Cartridge Set

BLUESERT™ 2.2 Injector for diopter range 0.0 to +24.0

ZEISS R28 IOL Delivery System with ZEISS Z28 Cartridge IOL

BLUESERT 2.4 Injector for diopter range +24.5 to +30.0

Delivery System for diopter range +4.0 to +34.0

BLUESERT 2.6 Injector for diopter range +30.5 to +34.0

* For optimized A Constants and ACD Constants refer to IOLCon: https://iolcon.org/lensesTable.php. Last retrieved 2019-02-28

ZEISS OPHTHALIN

Competitive viscous-cohesive OVD with high zero-shear viscosity5, being part of an efficient cataract workflow.
  

Get in touch with us!

Receive more information about the product and availability in your country!

Form is loading...

Personal contact information

If you want to have more information on data processing at ZEISS please refer to our data privacy notice. 

  • 1

    The data is taken from a simulation. The transferability of the results of such a simulation to patients with an actual implanted intraocular lense has not yet been scientifically proven. Whether the simulated impressions correspond to the actual visual impressions must be clarified in future invasive studies.
  • 2

    The heparin coating on the lens surface has no pharmacological, immunological or metabolic action.
  • 3

    Clinical Study in US with CT LUCIA 611 of same material did not show any glistenings at 12 months.
  • 4

    Data on file.

      
  • 5

    Viscosity at zero shear at 100.000 mPas.